Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, dNal (2′)8]-γ-MSH selectivity

Min Chen, Minying Cai, David McPherson, Victor J Hruby, Carroll M. Harmon, Yingkui Yang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The melanocortin receptor (MCR) subtype family is a member of the GPCR superfamily and each of them has a different pharmacological profile regarding the relative potency of the endogenous and synthetic melanocortin peptides. Substitution of Trp with dNal (2′) in γ-MSH resulted in the loss of binding affinity and potency at hMC4R. However, the molecular mechanism of this ligand selectivity is unclear. In this study, we utilized chimeric receptors and site-directed mutagenesis approaches to investigate the molecular basis of MC4R responsible for peptide [Pro5, dNal (2′)8]-γ-MSH selectivity. Cassette substitutions of the second, third, fourth, fifth, and sixth TM of the human MC4R (hMC4R) with the homologous regions of hMC1R were constructed and the binding affinity of peptide [Pro5, dNal (2′)8]-γ-MSH at these chimeric receptors was evaluated. Our results indicate that the cassette substitutions of TM2, TM3, TM4 and TM5 of hMC4R with homologous regions of the hMC1R did not significantly increase peptide [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency but substitution of the TM6 of the hMC4R with the same region of the hMC1R significantly enhances [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency. Further site-directed mutagenesis study indicates that four amino acid residues, Phe267, Tyr268, Ile269 and Ser270, in TM6 of the hMC4R may play an important role in [Pro5, dNal (2′)-γ-MSH selective activity at MC4R.

Original languageEnglish (US)
Pages (from-to)114-124
Number of pages11
JournalBiochemical Pharmacology
Volume77
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Receptor, Melanocortin, Type 4
Melanocyte-Stimulating Hormones
Peptides
Substitution reactions
Mutagenesis
Site-Directed Mutagenesis
Melanocortin Receptors
Melanocortins
Pharmacology
Ligands
Amino Acids

Keywords

  • γ-MSH
  • Agonist
  • GPCR
  • MC1R
  • MC4R
  • Obesity

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, dNal (2′)8]-γ-MSH selectivity. / Chen, Min; Cai, Minying; McPherson, David; Hruby, Victor J; Harmon, Carroll M.; Yang, Yingkui.

In: Biochemical Pharmacology, Vol. 77, No. 1, 01.01.2009, p. 114-124.

Research output: Contribution to journalArticle

@article{523eaafbd72e409eb5e48c67016bc637,
title = "Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, dNal (2′)8]-γ-MSH selectivity",
abstract = "The melanocortin receptor (MCR) subtype family is a member of the GPCR superfamily and each of them has a different pharmacological profile regarding the relative potency of the endogenous and synthetic melanocortin peptides. Substitution of Trp with dNal (2′) in γ-MSH resulted in the loss of binding affinity and potency at hMC4R. However, the molecular mechanism of this ligand selectivity is unclear. In this study, we utilized chimeric receptors and site-directed mutagenesis approaches to investigate the molecular basis of MC4R responsible for peptide [Pro5, dNal (2′)8]-γ-MSH selectivity. Cassette substitutions of the second, third, fourth, fifth, and sixth TM of the human MC4R (hMC4R) with the homologous regions of hMC1R were constructed and the binding affinity of peptide [Pro5, dNal (2′)8]-γ-MSH at these chimeric receptors was evaluated. Our results indicate that the cassette substitutions of TM2, TM3, TM4 and TM5 of hMC4R with homologous regions of the hMC1R did not significantly increase peptide [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency but substitution of the TM6 of the hMC4R with the same region of the hMC1R significantly enhances [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency. Further site-directed mutagenesis study indicates that four amino acid residues, Phe267, Tyr268, Ile269 and Ser270, in TM6 of the hMC4R may play an important role in [Pro5, dNal (2′)-γ-MSH selective activity at MC4R.",
keywords = "γ-MSH, Agonist, GPCR, MC1R, MC4R, Obesity",
author = "Min Chen and Minying Cai and David McPherson and Hruby, {Victor J} and Harmon, {Carroll M.} and Yingkui Yang",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.bcp.2008.09.023",
language = "English (US)",
volume = "77",
pages = "114--124",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, dNal (2′)8]-γ-MSH selectivity

AU - Chen, Min

AU - Cai, Minying

AU - McPherson, David

AU - Hruby, Victor J

AU - Harmon, Carroll M.

AU - Yang, Yingkui

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The melanocortin receptor (MCR) subtype family is a member of the GPCR superfamily and each of them has a different pharmacological profile regarding the relative potency of the endogenous and synthetic melanocortin peptides. Substitution of Trp with dNal (2′) in γ-MSH resulted in the loss of binding affinity and potency at hMC4R. However, the molecular mechanism of this ligand selectivity is unclear. In this study, we utilized chimeric receptors and site-directed mutagenesis approaches to investigate the molecular basis of MC4R responsible for peptide [Pro5, dNal (2′)8]-γ-MSH selectivity. Cassette substitutions of the second, third, fourth, fifth, and sixth TM of the human MC4R (hMC4R) with the homologous regions of hMC1R were constructed and the binding affinity of peptide [Pro5, dNal (2′)8]-γ-MSH at these chimeric receptors was evaluated. Our results indicate that the cassette substitutions of TM2, TM3, TM4 and TM5 of hMC4R with homologous regions of the hMC1R did not significantly increase peptide [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency but substitution of the TM6 of the hMC4R with the same region of the hMC1R significantly enhances [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency. Further site-directed mutagenesis study indicates that four amino acid residues, Phe267, Tyr268, Ile269 and Ser270, in TM6 of the hMC4R may play an important role in [Pro5, dNal (2′)-γ-MSH selective activity at MC4R.

AB - The melanocortin receptor (MCR) subtype family is a member of the GPCR superfamily and each of them has a different pharmacological profile regarding the relative potency of the endogenous and synthetic melanocortin peptides. Substitution of Trp with dNal (2′) in γ-MSH resulted in the loss of binding affinity and potency at hMC4R. However, the molecular mechanism of this ligand selectivity is unclear. In this study, we utilized chimeric receptors and site-directed mutagenesis approaches to investigate the molecular basis of MC4R responsible for peptide [Pro5, dNal (2′)8]-γ-MSH selectivity. Cassette substitutions of the second, third, fourth, fifth, and sixth TM of the human MC4R (hMC4R) with the homologous regions of hMC1R were constructed and the binding affinity of peptide [Pro5, dNal (2′)8]-γ-MSH at these chimeric receptors was evaluated. Our results indicate that the cassette substitutions of TM2, TM3, TM4 and TM5 of hMC4R with homologous regions of the hMC1R did not significantly increase peptide [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency but substitution of the TM6 of the hMC4R with the same region of the hMC1R significantly enhances [Pro5, dNal (2′)8]-γ-MSH binding affinity and potency. Further site-directed mutagenesis study indicates that four amino acid residues, Phe267, Tyr268, Ile269 and Ser270, in TM6 of the hMC4R may play an important role in [Pro5, dNal (2′)-γ-MSH selective activity at MC4R.

KW - γ-MSH

KW - Agonist

KW - GPCR

KW - MC1R

KW - MC4R

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=56649099031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649099031&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2008.09.023

DO - 10.1016/j.bcp.2008.09.023

M3 - Article

VL - 77

SP - 114

EP - 124

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 1

ER -